PREMMplus app to identify Lynch syndrome and other hereditary cancer risks
Design of a Scalable and Sustainable PREMMplus Patient-Facing App and Implementation in Three Healthcare Settings
This project builds a patient-facing PREMMplus app to help people and their doctors find genetic risks for Lynch syndrome and other hereditary cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11182562 on NIH RePORTER |
What this research studies
You would use an easy app to enter your family and personal cancer history and get a personalized risk estimate based on the PREMMplus model. The team will design the app to work at scale, connect with clinic systems (using standards like FHIR), and fit into normal appointments. They will roll the app out and refine how it works in three different healthcare settings to see how patients and providers use it. The goal is to make it simpler for clinics to identify people who should get genetic counseling or testing.
Who could benefit from this research
Good fit: Ideal candidates are adults with a personal or family history of colorectal, endometrial, or related cancers or patients in primary care who want to know their hereditary cancer risk.
Not a fit: People who already had comprehensive genetic testing with conclusive results, those without relevant family history, or those without access to the participating clinics or internet may not benefit.
Why it matters
Potential benefit: If successful, the app could help more people with hereditary cancer risk get identified earlier and receive appropriate genetic testing and preventive care.
How similar studies have performed: PREMM models are well validated and widely used with strong sensitivity, but deploying a scalable patient-facing PREMMplus app across multiple health systems is relatively new.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Syngal, Sapna — Dana-Farber Cancer Inst
- Study coordinator: Syngal, Sapna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.